Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761 For Autoimmune Diseases

• Immutep has completed the single ascending dose (SAD) portion of its IMP761 study 
• IMP761 was well tolerated across all dose levels
• IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026
   

SYDNEY, AUSTRALIA, March 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody which enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T cell responses in autoimmune diseases.

The Company reported that the single ascending dose (SAD) portion of the study has been successfully completed, with dosing up to 14 mg/kg. IMP761 was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed to date.

The study is currently progressing in the multiple ascending dose (MAD) portion, which is evaluating pharmacokinetics and safety across two dose levels. Completion of the MAD portion is expected in the third quarter of 2026.